Activity and tolerability of maintenance avelumab (AVE) immunotherapy after first-line platinum-based polychemotherapy in patients (pts) with locally advanced or metastatic squamous cell penile carcinoma: Initial results of PULSE study.

被引：0
|
作者：
Thiery-Vuillemin, Antoine
Tartas, Sophie
Mourey, Loic
Colomba, Emeline
Borchiellini, Delphine
Goujon, Morgan
Lefort, Felix
Topart, Delphine
Barthelemy, Philippe
Lauridant, Geraldine
Meurisse, Aurelia
Vernerey, Dewi
Massard, Vincent
机构：
[1] Ctr Hosp Reg Univ, Med Oncol, Besancon, France
[2] South Lyon Hosp Ctr, Lyon, France
[3] IUCT Oncopole, Inst Claudius Regaud, Toulouse, France
[4] Gustave Roussy, Villejuif, France
[5] Ctr Antoine Lacassagne, Nice, France
[6] CHRU Besancon, Inst Reg Fed Canc, Oncol Med, Besancon, France
[7] Univ Bordeaux, CHU Bordeaux, Dept Med Oncol, Hop St Andre, Bordeaux, France
[8] CHU Montpellier, Montpellier, France
[9] Inst Cancerol Strasbourg Europe, Strasbourg, France
[10] Les Dentellieres, Valenciennes, France
[11] Univ Hosp, Dept Oncol, Methodol & Qual Life Unit, INSERM UMR 1098, Besancon, France
[12] UMQVC, Besancon, France
[13] Univ Hosp Besancon, Besancon, France
[14] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Observational, prospective, phase 4 study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT
    Guigay, Joel
    Chamorey, Emmanuel
    Lefebvre, Gautier
    Rotarski, Maciej
    Wagner, Jean-Philippe
    Blot, Emmanuel
    Alfonsi, Marc
    Seronde, Audrey
    Schulten, Jeltje
    Peyrade, Frederic
    Le Tourneau, Christophe
    CANCER REPORTS, 2022, 5 (02)
  • [22] MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)
    Gupta, Shilpa
    Ballman, Karla V.
    Galsky, Matt D.
    Morris, Michael J.
    Chen, Ronald C.
    Chan, Timothy A.
    Dercle, Laurent
    Wen, Yujia
    Sridhar, Srikala S.
    Yen, Aihua Edward
    Grivas, Petros
    Tan, Alan
    Baghaie, Shiva
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Avelumab first-line maintenance (1LM) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic: Interim real-world results from a national reimbursement registry.
    Zemankova, Anezka
    Studentova, Hana
    Melichar, Bohuslav
    Eid, Michal
    Poprach, Alexandr
    Kopecky, Jindrich
    Spacek, Jan
    Stuhlova, Sarka
    Dvorak, Jan
    Vlcek, Pavel
    Zychackova, Katerina
    Katolicka, Jana
    Blazek, Tomas
    Vrana, David
    Majkova, Petra
    Cepa, Adam
    Fiala, Ondrej
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 557 - 557
  • [24] A single-arm, exploratory study of disitamab vedotin (DV) combined with camrelizumab and platinum-based chemotherapy as first-line treatment in patients with HER2 expressing locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).
    Wu, Meihong
    Zhang, Yingyi
    Feng, Dan
    Wang, Bin
    Wang, Wei
    Chen, Tianran
    Zhao, Anjing
    Xu, Meng
    Zhang, Linli
    Zhan, Xianbao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS217 - TPS217
  • [25] Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study
    Miyake, Makito
    Shimizu, Takuto
    Oda, Yuki
    Tachibana, Akira
    Ohmori, Chihiro
    Itami, Yoshitaka
    Kiba, Keisuke
    Tomioka, Atsushi
    Yamamoto, Hiroaki
    Ohnishi, Kenta
    Nishimura, Nobutaka
    Hori, Shunta
    Morizawa, Yosuke
    Gotoh, Daisuke
    Nakai, Yasushi
    Torimoto, Kazumasa
    Fujii, Tomomi
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (03) : 253 - 262
  • [26] PREDICTORS OF EFFICACY IN THE EXTREME STUDY: CETUXIMAB PLUS PLATINUM-BASED THERAPY FIRST-LINE IN PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Vermorken, J. B.
    Mesia, R.
    Remenar, E.
    Erfan, J.
    Zabolotnyy, D.
    Benasso, M.
    Koralewski, P.
    Gross, A.
    Stroh, C.
    Bokemeyer, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 217 - 217
  • [27] PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.
    Ciardiello, Fortunato
    Bang, Yung-Jue
    Bendell, Johanna C.
    Cervantes, Andres
    Dvorkin, Mikhail
    Lopez, Charles D.
    Metges, Jean-Philippe
    Sanchez, Antonio
    Calvo, Mariona
    Strickland, Andrew
    Kannourakis, George
    Muro, Kei
    Kawakami, Hisato
    Wei, Jia
    Borg, Christophe
    Mu, Song
    Zhang, Kathy
    Zhang, Maggie
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Non-interventional Study of Avelumab in the Treatment of Urothelial Cancer - The AVENUE NIS - AB 82/21 of AUO First-line Maintenance Therapy in Adult Patients with locally advanced or metastatic Urothelial Cancer who are progression-free after platinum-based Chemotherapy
    不详
    UROLOGIE, 2023, 62 (06): : 672 - 673
  • [29] PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.
    Grivas, Petros
    Barata, Pedro C.
    Moon, Helen
    Hutson, Thomas E.
    Gupta, Shilpa
    Sternberg, Cora N.
    Pickard, A. Simon
    Dave, Vaidehi
    Han, Natalia
    Shillington, Alicia C.
    Devgan, Geeta
    Kim, Ruth
    Thakkar, Sheena
    Katzenstein, Howard
    Bhanegaonkar, Abhijeet
    Liu, Frank
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [30] MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
    Gupta, Shilpa
    Ballman, Karla V.
    Apolo, Andrea B.
    Sridhar, Srikala S.
    Chen, Ronald C.
    Wen, Yujia
    Yen, Aihua Edward
    Grivas, Petros
    Tan, Alan
    Baghaie, Shiva
    Galsky, Matt D.
    Morris, Michael J.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS714 - TPS714
12345